MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Visualising tau in patients with progressive supranuclear palsy using PI2620-PET

    L. Vivash, HM. Tang, K. Bertram, TJ. O'Brien (Melbourne, Australia)

    Objective: This study investigates the use of a new tau-specific PET radiotracer, [18F]-PI-2620, as a tool for visualising tau in the living brain. Background: The…
  • MDS Virtual Congress 2021

    Pallidal recordings in fully implanted dystonic patients: preliminary results

    C. Palmisano, P. Capetian, Y. Thenaisie, A. Canessa, E. Moraud, M. Contarino, I. Isaias (Würzburg, Germany)

    Objective: To describe oscillatory patterns of pallidal local field potentials (LFP) in fully implanted patients with dystonia. ​​​ Background: New implantable devices for deep brain stimulation…
  • MDS Virtual Congress 2021

    How can patients’ trajectories inform the co-design of an integrated care network for people living with Parkinson’s Disease?

    S. Grosjean, J. Farré Coma, O. Gal, A. Laffan, A. Sendra, J. Stuempel, T. Mestre (Ottawa, Canada)

    Objective: The aim of this study is to provide a better understanding of how patients’ experience could inform the design of an integrated care network…
  • MDS Virtual Congress 2021

    Direct Costs of patients with Parkinson’s Disease in a region of the Brazilian Amazon

    R. Feio, T. França, A. Passos, A. Silva, A. Escudeiro, B. Koshimoto, D. Moura, B. Lobato (Belém, Brazil)

    Objective: To evaluate the perception of the annual direct costs (medications, medical appointments, rehabilitation, transportation) associated with the treatment for patients with PD in the…
  • MDS Virtual Congress 2021

    Hyperkinetic Movement Disorders after Thalamic Lesions

    S. Torabi, Y. Kianirad (Chicago, USA)

    Objective: To describe delayed hyperkinetic movement disorder after a thalamic lesion. Background: Lesions in the basal ganglia circuit can cause abnormal movement disorders.  After thalamic…
  • MDS Virtual Congress 2021

    Pharmacokinetic–pharmacodynamics of levodopa/carbidopa following subcutaneous infusion with ND0612: Results from the BeyoND pharmacokinetic substudy

    T. Birnberg, L. Adar, W. Poewe, M. Bjornsson, M. Karlsson (Rehovot, Israel)

    Objective: To evaluate the pharmacokinetic–pharmacodynamic relationships between levodopa plasma exposure and motor treatment response in patients with Parkinson’s disease (PD) treated with ND0612 and adjunct…
  • MDS Virtual Congress 2021

    Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Impact on Impulse Control Disorders

    A. Espay, K. Markopoulou, I. Zhang, E. Pappert, B. Navia (Cincinnati, USA)

    Objective: Assess impact of apomorphine sublingual film (APL) on impulse control disorders (ICDs) in patients with Parkinson’s disease (PD) and “OFF” episodes. Background: In a…
  • MDS Virtual Congress 2021

    FIRST-IN-MAN CLINICAL TRIAL OF INTRAPUTAMENAL CDNF IN PARKINSON’S DISEASE FINDS A CONSORTED BIOMARKER RESPONSE IN A SUBGROUP OF SUBJECTS

    H. Huttunen, S. Booms, M. Sjögren, A. Cryar, J. Harris, E. Sirka, M. Dove, N. Majbour, H. Abdesselem, O. El-Agnaf, J. Koskinen, R. Holmnäs, V. Kerstens, J. Johansson, J. Rinne, A. Varrone, M. Woolley, B. Murphy, P. Fielder, J. Baker, P. Skinner, M. Andreasson, G. Paul-Visse, R. Kivisaari, H. Bjartmarz, G. Lind, P. Almqvist, F. Scheperjans, H. Widner, P. Svenningsson (Espoo, Finland)

    Objective: In the first-in-man clinical study of intermittent intraputamenal monthly infusions of CDNF in subjects with moderately advanced PD, we explored cerebrospinal fluid (CSF) biomarkers…
  • MDS Virtual Congress 2021

    Reversible MIBG Abnormalities in Subjects at Risk for Synucleinopathy: 12 months data

    H. Maghzi, E. Hogg, E. Tan, G. Obiliasi, G. Pagano, M. Tagliati (Los Angeles, USA)

    Objective: To investigate the long-term effects of the adrenergic blocker carvedilol on I-MIBG myocardial uptake in subjects with REM sleep behavior disorder (RBD) and other…
  • MDS Virtual Congress 2021

    Randomised Controlled Trial Comparing Efficacy of Zonisamide 25 mg given in addition to standard treatment with standard treatment alone in Tremor dominant Parkinson’s Disease- A Pilot study.

    K. Pillai, V. Goyal, A. Srivastava, R. Rajan, P. Srivastava, M. Singh, V. V.Y, D. Radhakrishnan, A. Elavarasi, P. Bhat (New Delhi, India)

    Objective: To compare improvement in  tremor at 12 weeks with Zonisamide  given in  a dose of  25 mg  along with other ant- parkinsonian drugs as…
  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley